Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis

BACKGROUND: Currently, three chimeric antigen receptor (CAR)-T cell products axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel have been approved by the U.S. Food and Drug Administration for the treatment of large B cell lymphoma, which provide a novel and promising choice for...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Jun, Wu, XiaoQin, Sun, Zhen, Xun, RenDe, Liu, MengSi, Hu, Rui, Huang, JianChao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350577/
https://www.ncbi.nlm.nih.gov/pubmed/34381720
http://dx.doi.org/10.3389/fonc.2021.698607

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350577/
https://www.ncbi.nlm.nih.gov/pubmed/34381720
http://dx.doi.org/10.3389/fonc.2021.698607

Ejemplares similares